arrow
S

Sarbjit S. Saini

Genentech
H指数:55
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria

慢性自发性荨麻疹患者中Ligelizumab作为再治疗的长效疗效与安全性

2025-12-080
OAAI
Remibrutinib in chronic spontaneous urticaria: 52-Week results from two phase 3 studies

Remibrutinib在慢性自发性荨麻疹中的应用:两项III期研究52周结果

2025-10-180
PRE
A mast cell receptor mediates post-stroke brain inflammation via a dural-brain axis

肥大细胞受体通过硬脑膜-脑轴介导卒中后脑部炎症

Cell
IF42.5
2025-07-240
OAAI
Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis

生物制剂与系统性免疫调节治疗慢性荨麻疹的疗效与安全性比较:系统评价和网络Meta分析

2025-07-150
OAAI
A Mast Cell-Specific Receptor Mediates Post-Stroke Brain Inflammation Via a Dural-Brain Axis

一种肥大细胞特异性受体通过硬脑膜-脑轴介导卒中后脑部炎症

STROKE
IF8.9
2025-02-010
PRE
Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

系统性糖皮质激素治疗荨麻疹的有效性和安全性: 随机临床试验的系统评价和荟萃分析

2024-07-015
OAAI
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

慢性自发性荨麻疹患者的Dupilumab (liberte-csu CUPID): 两项随机,双盲,安慰剂对照的3期试验

2024-07-0118
OAAI
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
LANCET
IF88.5
2024-01-0113
PRE